Evinacumab · Evkeeza
Monoclonal antibody
Also known as REGN1500
Evidence outlook
Approved: Homozygous Familial Hypercholesterolemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (3)
- Treatment of homozygous familial hypercholesterolemia
- EVKEEZA® (evinacumab for injection) is indicated as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients 6 months of age and older with homozygous familial hypercholesterolemia (HoFH). The effects of Evkeeza on cardiovascular morbidity and mortality have not been determined.
- Evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03399786 NCT03399786 · Homozygous Familial Hypercholesterolemia The trial randomized 65 participants to evinacumab or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary LDL-C endpoint was statistically significantly improved with evinacumab, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure. Registry: NCT03399786 | 3 | Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) 2019-06-10 | Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5) | Partial signal | link ↗ |
View 2 more trials
NCT04233918 NCT04233918 · Homozygous Familial Hypercholesterolemia The study was open-label, single-arm, and had no placebo or active comparator; it enrolled 20 participants overall, with 14 contributing to the main LDL-C analysis. Its primary outcomes included pharmacokinetic measures and LDL-C change, but there was no randomized comparison or formal primary endpoint significance test, so the findings provide limited evidence of treatment effectiveness. Registry: NCT04233918 | 3 | Part A: Maximum Observed Serum Concentration (Cmax) of Evinacumab (At day 12); Part A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Evinacumab (Up to Week 12); Part A: Terminal Half-Life (t1/2) of Evinacumab (Up to week 12); Part B: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 2022-01-31 | Part A: Maximum Observed Serum Concentration (Cmax) of Evinacumab (At day 12): Part A: Evinacumab 15mg/Kg IV 238 Milligrams per Liter (mg/L) (Standard Deviation 90.8) | Weak signal | link ↗ |
NCT03409744 NCT03409744 · Homozygous Familial Hypercholesterolemia The study was an open-label, single-arm continuation of a parent study, enrolling 116 treated participants without randomization or a control group. Its primary safety endpoint was descriptive rather than a comparative efficacy test, so the results provide useful long-term follow-up but limited evidence about treatment effects. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT03409744 | 3 | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216 (Up to 216 weeks) 2023-04-13 | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216 (Up to 216 weeks): Overall Study Total Evinacumab — Participants with any TEAE: 93 Number of participants; Participants with at least one serious TEAE: 27 Number of participants | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other ANGPTL3 drugs
SHR-1918, ALN-ANG3, BW-00112, EDP167, Solbinsiran and 3 more. Compare all 9 ANGPTL3 drugs
This mechanism is crowded: 9 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Homozygous Familial Hypercholesterolemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Evinacumab (Evkeeza): this drug | Approved | Monoclonal antibody | ANGPTL3 | Partial signal | NCT03399786: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5) | |
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | Partial signal | NCT03156621: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3) | |
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | Reliable signal | NCT01588496: Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001 | |
| Ezetimibe (Zetia) | Approved | Small molecule | Dietary Cholesterol Absorption Inhibitor, NPC1L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ezetimibe / Simvastatin (Vytorin) | Approved | Small molecule | HMG-CoA reductase / NPC1L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | Partial signal | NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) | |
| Lomitapide (Juxtapid) | Approved | Small molecule | MTP | Weak signal | NCT04681170: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline (Baseline through Week 24): Age 5-10 Years -56.529% (Standard Deviation 26.5401) | Age 11-17 Years -51.633% (Standard Deviation 25.5658) NCT02173158: Percent Change in LDL-C (Baseline to Week 26): Lomitapide -42.2% (Standard Deviation 18.16) | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1918 | Phase 3 | Monoclonal antibody | ANGPTL3 | Partial signal | NCT06723652: LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026 | |
| Zodasiran | Phase 3 | RNA / oligonucleotide | ANGPTL3 gene mRNA (hepatic) | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-ANG3 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BW-00112 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| EDP167 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Solbinsiran | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| SYH2070 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| CTX310 | Phase 1(overall) | Gene therapy / editing | ANGPTL3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| NNC0491-6075 | Phase 1(overall) | Monoclonal antibody | ANGPTL3 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| AZD1705 | Discontinued | RNA / oligonucleotide | ANGPTL3 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Evkeeza (Evinacumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.